tazobactam has been researched along with cefepime in 100 studies
Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (cefepime) | Trials (cefepime) | Recent Studies (post-2010) (cefepime) |
---|---|---|---|---|---|
1,327 | 153 | 694 | 1,737 | 186 | 684 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (6.00) | 18.2507 |
2000's | 32 (32.00) | 29.6817 |
2010's | 37 (37.00) | 24.3611 |
2020's | 25 (25.00) | 2.80 |
Authors | Studies |
---|---|
Bonnet, R; Chanal, C; Delmas, J; Lesens, O; Robin, F; Schweitzer, C; Tournilhac, O | 1 |
Aubert, D; Naas, T; Nordmann, P; Ozcan, A | 1 |
Arlet, G; Loli, A; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
Cattoir, V; Corvec, S; Drugeon, H; Faccone, D; Galas, M; Mugnier, P; Nordmann, P; Pasteran, F; Petroni, A; Poirel, L; Rapoport, M | 1 |
Ayala, JA; Casellas, JM; Di Conza, J; Ghiglione, B; Gutkind, G; Power, P; Radice, M; Rodríguez, MM | 1 |
Amicosante, G; Caporale, B; Celenza, G; Docquier, JD; Mezzatesta, M; Pellegrini, C; Perilli, M; Rossolini, GM; Stefani, S | 1 |
Bush, K; Kania, M; Page, MG; Queenan, AM; Shang, W | 1 |
Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
Bonnet, R; Brebion, A; Constantin, JM; Delmas, J; Dubois, D; Robin, F | 1 |
Girlich, D; Leclercq, R; Naas, T; Nordmann, P | 1 |
Courvalin, P; Decré, D; Høiby, EA; Meziane-Cherif, D; Périchon, B | 1 |
Bonnet, R; Caniça, M; Ferreira, E; Manageiro, V; Mendonça, N; Robin, F; Salgado, MJ | 1 |
Castanheira, M; Samuelsen, Ø; Spencer, J; Walsh, TR | 1 |
Andlovic, A; Jeverica, S; Karisik, E; Koren, S; Krizan-Hergouth, V; Livermore, DM; Mesko Meglic, K; Müller-Premru, M; Palepou, MF; Pike, R; Seme, K; Woodford, N | 1 |
Nordmann, P; Plésiat, P; Poirel, L; Rodriguez-Martinez, JM | 1 |
Bonnet, R; Brisabois, A; Cloeckaert, A; Doublet, B; Fabre, L; Granier, SA; Robin, F; Weill, FX | 1 |
Chanteperdrix, V; Croizé, J; Nordmann, P; Poirel, L; Potron, A | 1 |
Kotsakis, SD; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
Bonnet, R; Casin, I; Doublet, B; Fabre, L; Le Fleche, A; Robin, F; Weill, FX | 1 |
De Luca, F; Docquier, JD; Ide, L; Nordmann, P; Poirel, L; Rossolini, GM; Verlinde, A | 1 |
Girlich, D; Nordmann, P; Poirel, L | 1 |
Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
Choi, JY; Ko, KS; Lee, MY; Park, YK; Peck, KR; Rhee, JY; Shin, JY; Song, JH | 1 |
Abendroth, J; Atkins, K; Boyer, SH; Clifton, MC; Dudley, MN; Durso, S; Griffith, DC; Hecker, SJ; Hirst, GC; King, P; Lomovskaya, O; Loutit, JS; Morgan, EE; Potts, KT; Raymond, A; Reddy, KR; Sabet, M; Sun, D; Tarazi, Z; Totrov, M; Tsivkovski, R | 1 |
Colchón, E; González-Bello, C; Pernas, M; Rodríguez, Á; Rodríguez, D | 1 |
Benvenuti, M; Burns, CJ; Chu, GH; Cusick, SM; Daigle, DM; De Luca, F; Docquier, JD; Hamrick, JC; Jackson, RW; Liu, B; Mangani, S; McGarry, D; Pevear, DC; Pozzi, C; Trout, REL; Weiss, WJ; Xerri, L | 1 |
Dornbusch, K; Göransson, E; Mörtsell, E | 1 |
Cony Makhoul, P; Darmaillac, V; Fourche, J; Maugein, J; Perrier, F | 1 |
Harris, EB; Hastings, RC; Prabhakaran, K; Randhawa, B | 1 |
Eliopoulos, GM; Moellering, RC; Thauvin-Eliopoulos, C; Tripodi, MF | 1 |
Böhme, A; Hoelzer, D; Shah, PM; Stille, W | 1 |
Kays, MB | 1 |
Moland, ES; Thomson, KS | 1 |
Batlle, M; Benlloch, L; Capote, FJ; Gutiérrez, M; Jarque, I; Julià, A; Lahuerta, JJ; Larrea, L; López, J; Palau, J; Pérez, C; Ramos, F; Rovira, M; Sanz, MA; Vázquez, L | 1 |
Jones, RN; Mutnick, AH; Turner, PJ | 1 |
Burgess, DS; Nathisuwan, S | 1 |
Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH | 1 |
Choi, MK; Fish, DN; Husain, M; Jung, R | 1 |
Bethel, CR; Bonomo, RA; Helfand, MS; Hujer, AM | 1 |
Burgess, DS; Hall, RG | 1 |
Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
Capparelli, FJ; Del Castillo, ME; Diaz, MF; Hlavnika, A; Leiguarda, R; Wainsztein, NA | 1 |
Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
Arora, J; Dogra, A; Rao, P; Taneja, N | 1 |
Kulkarni, KP; Pal, P; Pal, RB; Venkatesh, V | 1 |
Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X | 1 |
Adams, CA; Cioffi, WG; Connolly, MD; Gregg, S; Heffernan, DS; Monaghan, SF; Stephen, A; Thakkar, RK | 1 |
Chander, J; Garg, R; Gulati, N; Gupta, V; Krishnan, P; Kumarasamy, K | 1 |
Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
Arakawa, S; Fujisawa, M; Miyake, H; Shigemura, K; Tanaka, K | 1 |
Dharuman, JG; Vasudevan, M | 1 |
Gautam, V; Kaur, R; Ray, P; Singhal, L | 1 |
Frey, L; Maier, B; Suhr, A; Teupser, D; Vogeser, M; Zander, J; Zoller, M | 1 |
Al-Attas, A; Belal, F; El-Enany, N; Nasr, JJ | 1 |
Nicolau, DP; Sutherland, CA | 1 |
Berrazeg, M; Broutin, I; Fournier, D; Jeannot, K; Loeffert, S; Ntsogo Enguéné, VY; Plésiat, P | 1 |
Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
Manian, FA | 1 |
Kaye, KS; Navalkele, B; Pogue, JM | 1 |
Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
Mueller, BA; Shaw, AR | 1 |
Flamm, RK; Huband, MD; Jones, RN; Riedel, S; Sader, HS | 1 |
Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
Coburn, B; Daneman, N; MacFadden, DR | 1 |
Kollef, MH; Micek, ST; Vazquez Guillamet, MC; Vazquez, R | 1 |
Livermore, DM; Mushtaq, S; Turner, SJ; Warner, M; Woodford, N | 1 |
Bansal, N; Gopalakrishnan, R; Kumar D, S; Nambi, PS; Ramasubramanian, V; Sukhwani, KS | 1 |
Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS; Shortridge, D | 1 |
An, G; Bach, T; D'Cunha, R; Li, P; Nalbant, D; Winokur, P; Young, BA; Zhang, J | 2 |
Farkas, A; Heil, EL; Nicolau, DP; Roberts, JA; Thom, KA | 1 |
Blevins, AM; Juang, P; Kollef, M; Lashinsky, JN; McCammon, C; Micek, S | 1 |
Beaulieu, C; Kurczewski, L; Yajnik, V | 1 |
Banerjee, R; Esbenshade, AJ; Quach, HT; Zhao, Z | 1 |
Albanèse, J; Bornet, C; Curti, C; Fersing, C; Guinard, B; Lamy, E; Mathias, F; Primas, N; Souab, HK; Vanelle, P | 1 |
Aboklaish, AF; Brem, J; Jackson, DE; Langley, GW; Schofield, CJ; Tselepis, L; Tyrrell, JM; Walsh, TR; Widlake, E | 1 |
Dorn, C; Hitzenbichler, F; Kees, F; Kees, M; Liebchen, U; Paal, M; Schiesser, S | 1 |
Al-Shaer, MH; Alghamdi, WA; Peloquin, C | 1 |
Abdelraouf, K; Gill, CM; Nicolau, DP | 1 |
Garello, P; Livermore, DM; Mushtaq, S; Vickers, A; Woodford, N | 1 |
Barreto, EF; Bjergum, MW; Jannetto, PJ; Rule, AD; Scheetz, MH | 1 |
Burgess, DS; Clark, JA; Landmesser, KB | 1 |
Imai, S; Itoh, T; Kadomura, S; Kashiwagi, H; Momo, K; Sato, Y; Sugawara, M; Takekuma, Y | 1 |
Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS | 1 |
Alonso-Ramos, H; Barrera-Cabeza, J; Cordero-Ramos, J; Fernández-Del-Castillo, SS; Hoxha, M; Moya-Martin, M; Murillo-Izquierdo, M; Nunez-Nunez, M; Oltra-Hostalet, F; Quesada Pérez, MT; Retamar-Gentil, P | 1 |
Sun, J; Xie, L; Xu, R; Zhu, D | 1 |
Carvalhaes, CG; Castanheria, M; Duncan, LR; Mendes, RE; Sader, HS | 1 |
Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Oliver, A; Rumbo-Feal, S; Vázquez-Ucha, JC | 1 |
Babiak, P; Cizmarova, I; Kovac, A; Mikus, P; Parrak, V; Piestansky, J; Secnik, P | 1 |
Al Jalali, V; Ballarini, N; Bauer, M; Bergmann, F; Jorda, A; König, F; Lackner, E; Nussbaumer-Pröll, A; Oesterreicher, Z; Reiter, B; Stimpfl, T; Wölfl-Duchek, M; Wulkersdorfer, B; Zeitlinger, M | 1 |
Azam, N; Cherkaoui, A; Crudeli, L; Fernandez, J; Fischer, A; Renzi, G; Schorderet, D; Schrenzel, J | 1 |
Attwood, M; Chavan, R; MacGowan, A; Muller, AE; Noel, A; Periasamy, H; Van den Berg, S | 1 |
Gill, CM; Nicolau, DP | 2 |
Caljon, B; Crombé, F; De Geyter, D; Demuyser, T; Janssen, T; Muyldermans, A; Piérard, D; Seyler, L; Vanstokstraeten, R; Wybo, I | 1 |
Belley, A; Kaye, KS; Velicitat, P | 1 |
Hsu, CK; Lai, CC; Tsai, WW | 1 |
Deng, T; Kong, W; Li, S; Shu, Y; Wu, Y | 1 |
6 review(s) available for tazobactam and cefepime
Article | Year |
---|---|
β-Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactamases; Drug Resistance, Microbial; Humans; Protein Structure, Secondary; Protein Structure, Tertiary; Treatment Outcome | 2020 |
Role of pharmacodynamics in designing dosage regimens for beta-lactams.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Dose-Response Relationship, Drug; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2003 |
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Enzyme Inhibitors; Fever; Humans; Neutropenia; Penicillanic Acid; Penicillins; Quality Assurance, Health Care; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2006 |
Antibiotic Dosing in Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Critical Illness; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Renal Replacement Therapy; Sepsis; Tazobactam; Thienamycins | 2017 |
Compatibility of prolonged infusion antibiotics during Y-site administration.
Topics: Anti-Bacterial Agents; Cefepime; Humans; Infusions, Intravenous; Meropenem; Tazobactam | 2022 |
Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Humans; Intraabdominal Infections; Meropenem; Metronidazole; Network Meta-Analysis; Tazobactam; Tigecycline | 2023 |
6 trial(s) available for tazobactam and cefepime
Article | Year |
---|---|
Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
Topics: Anti-Infective Agents; Cefepime; Cephalosporins; Drug Therapy, Combination; Fever; Humans; Neutropenia; Penicillanic Acid; Pilot Projects; Piperacillin; Prognosis; Prospective Studies; Tazobactam | 1998 |
Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2002 |
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime.
Topics: Acute Kidney Injury; Adolescent; Cefepime; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Male; Piperacillin; Retrospective Studies; Tazobactam; Vancomycin | 2019 |
Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volunteers.
Topics: Anti-Bacterial Agents; Cefepime; Drugs, Generic; Healthy Volunteers; Humans; Linezolid; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Therapeutic Equivalency | 2022 |
Fully Automated EUCAST Rapid Antimicrobial Susceptibility Testing (RAST) from Positive Blood Cultures: Diagnostic Accuracy and Implementation.
Topics: Anti-Bacterial Agents; beta-Lactamases; Blood Culture; Cefepime; Ceftazidime; Humans; Imipenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Prospective Studies; Tazobactam | 2022 |
88 other study(ies) available for tazobactam and cefepime
Article | Year |
---|---|
Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.
Topics: beta-Lactamases; Drug Resistance, Bacterial; Escherichia coli; Evolution, Molecular; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation | 2007 |
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
Topics: beta-Lactamases; Chromosomes; Chromosomes, Bacterial; Citrobacter; Cloning, Molecular; DNA, Bacterial; Escherichia coli; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Genes, Bacterial; Molecular Sequence Data | 2007 |
SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Escherichia coli; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillinase; Plasmids; Sequence Analysis, DNA | 2007 |
Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
Topics: Acinetobacter; Acinetobacter Infections; Amino Acid Sequence; Anti-Bacterial Agents; Argentina; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Clavulanic Acid; Cloning, Molecular; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2007 |
Biochemical characterization of PER-2 and genetic environment of blaPER-2.
Topics: Amino Acid Sequence; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Catalysis; Citrobacter freundii; Conjugation, Genetic; DNA, Bacterial; DNA, Recombinant; Enterobacteriaceae; Genes, Bacterial; Humans; Hydrolysis; Isoelectric Focusing; Kinetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Sequence Data; Molecular Weight; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Conformation; Protein Sorting Signals; Sequence Analysis, DNA | 2007 |
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cephalosporins; Chryseobacterium; Flavobacteriaceae Infections; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Sequence Analysis, DNA | 2007 |
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Hydrolysis; Kinetics; Microbial Sensitivity Tests; Spectrophotometry, Ultraviolet | 2007 |
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
Topics: Anti-Bacterial Agents; Cephalosporinase; Culture Media; DNA Primers; Drug Resistance, Bacterial; Escherichia coli; Kinetics; Models, Molecular; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Spectrophotometry, Ultraviolet | 2007 |
TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
Topics: beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Catalysis; Ceftazidime; Clavulanic Acid; Escherichia coli; Escherichia coli Proteins; Isoenzymes; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2007 |
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
Topics: Amino Acid Sequence; Bacillus; Bacterial Proteins; beta-Lactamases; Chromosome Mapping; Chromosomes, Bacterial; Cloning, Molecular; Microbial Sensitivity Tests; Molecular Sequence Data; Molecular Weight; Sequence Homology, Amino Acid; Substrate Specificity | 2007 |
Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
Topics: Amino Acid Sequence; beta-Lactams; Chromosomes, Bacterial; Cloning, Molecular; Electrophoresis, Gel, Pulsed-Field; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Infant, Newborn; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillin Resistance; Penicillinase; Sequence Alignment; Sequence Analysis, DNA; Substrate Specificity | 2008 |
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Arginine; Aztreonam; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acid; Computer Simulation; Imipenem; Isoelectric Focusing; Kinetics; Klebsiella pneumoniae; Lysine; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Penicillins; Protein Conformation; Protein Structure, Tertiary | 2008 |
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
Topics: Acremonium; Bacterial Proteins; beta-Lactamases; Catalysis; Catalytic Domain; Cefepime; Ceftazidime; Cephalosporins; Kinetics; Models, Molecular; Mutation; Penicillinase; Protein Structure, Tertiary; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2008 |
Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
Topics: Anti-Bacterial Agents; beta-Lactamases; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Klebsiella pneumoniae; Microbial Sensitivity Tests; Slovenia | 2009 |
Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
Topics: Alleles; Amino Acid Sequence; Amino Acid Substitution; Base Sequence; beta-Lactamases; Burkholderia cepacia complex; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Hydrolysis; Isoelectric Point; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2009 |
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cardiidae; Ceftazidime; Ceftriaxone; Cephalosporin Resistance; Electrophoresis, Gel, Pulsed-Field; France; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Salmonella enterica; Serotyping | 2009 |
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Escherichia coli; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed | 2009 |
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
Topics: Aztreonam; beta-Lactamases; beta-Lactams; Ceftazidime; Cephalosporins; Escherichia coli Proteins; Protein Binding; Protein Structure, Secondary | 2009 |
Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Catheters, Indwelling; Chromosomes, Bacterial; Cloning, Molecular; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Genetic Variation; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Pseudomonas; Pseudomonas Infections; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Substrate Specificity | 2010 |
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
Topics: Belgium; beta-Lactamases; Cephalosporinase; Cephalosporins; Cross Infection; Escherichia coli; Genes, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blotting, Southern; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; France; Fresh Water; Gram-Negative Bacteria; Health Surveys; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas fluorescens; Water Microbiology | 2010 |
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
Topics: Aged; beta-Lactamases; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Klebsiella Infections; Klebsiella pneumoniae; Male; Renal Dialysis; Republic of Korea | 2010 |
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Boronic Acids; Carbapenems; Crystallography, X-Ray; Drug Resistance, Bacterial; Drug Synergism; Gram-Negative Bacteria; Heterocyclic Compounds, 1-Ring; Mice; Microbial Sensitivity Tests; Models, Molecular; Rats; Stereoisomerism; Structure-Activity Relationship | 2015 |
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactam Resistance; beta-Lactamase Inhibitors; Borinic Acids; Carbapenems; Carboxylic Acids; Humans; Mice; Models, Molecular | 2020 |
In vitro activity of cefepime, a new parenteral cephalosporin, against recent European blood isolates and in comparison with piperacillin/tazobactam.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Microbial; Drug Synergism; Enterobacteriaceae; Gram-Negative Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Piperacillin; Staphylococcus; Tazobactam | 1990 |
[In vitro activity of six beta-lactams against 295 strains of enterobacteriaceae and P. aeruginosa isolated from neutropenic patients].
Topics: Cefepime; Cefotaxime; Cefpirome; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 1995 |
beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cell Division; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Isoniazid; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium avium; Penicillanic Acid; Streptomycin; Sulbactam; Tazobactam | 1995 |
Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.
Topics: Abdominal Abscess; Animals; beta-Lactamases; Cefepime; Cephalosporins; Drug Therapy, Combination; Enzyme Inhibitors; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Rats; Rats, Sprague-Dawley; Tazobactam | 1997 |
Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
Topics: Anti-Bacterial Agents; Bacteria; Cefepime; Ceftazidime; Cephalosporins; Creatinine; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Piperacillin; Tazobactam; Time Factors | 1999 |
Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Chromosomes, Bacterial; Drug Resistance, Microbial; Enterobacteriaceae; Enzyme Inhibitors; Escherichia coli; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 2001 |
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins | 2002 |
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
Topics: Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sensitivity and Specificity; Tazobactam | 2002 |
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Colony Count, Microbial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Enzyme Inhibitors; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Moxifloxacin; Penicillanic Acid; Penicillins; Piperacillin; Quinolines; Tazobactam | 2004 |
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Escherichia coli; Escherichia coli Infections; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2004 |
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Culture Media, Conditioned; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam; Thienamycins | 2004 |
Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Brain; Cefepime; Cefixime; Cephalosporins; Confusion; Consciousness Disorders; Delirium; Epididymitis; Humans; Kidney; Male; Metabolic Clearance Rate; Neurotoxicity Syndromes; Penicillanic Acid; Piperacillin; Recovery of Function; Secondary Prevention; Systemic Inflammatory Response Syndrome; Tazobactam; Urinary Tract Infections; Withholding Treatment | 2005 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Humans; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Urinary Tract Infections | 2008 |
Evaluation of sensitivity of different organisms to cefepime and tazobactum (megapime XP) in comparison to cefepime and ceftazidime.
Topics: Anti-Bacterial Agents; Bacteria; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Gram-Positive Bacteria; Penicillanic Acid; Tazobactam | 2008 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Sepsis; Shock, Septic; Tazobactam; Thienamycins | 2010 |
Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
Topics: Acetamides; Anti-Bacterial Agents; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Oxazolidinones; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Retrospective Studies; Tazobactam; Treatment Outcome; Vancomycin; Wounds and Injuries | 2013 |
AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Humans; India; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2012 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement.
Topics: Aged; Anti-Bacterial Agents; Bacteriuria; Cefepime; Cephalosporins; Colon, Sigmoid; Cystectomy; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Postoperative Complications; Prevalence; Pyuria; Staphylococcus aureus; Sulfamethoxazole; Tazobactam; Thienamycins; Trimethoprim; Urinary Diversion; Urinary Tract Infections | 2014 |
Reliability-targeted HPLC-UV method validation--a protocol enrichment perspective.
Topics: Bayes Theorem; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Humans; Penicillanic Acid; Reproducibility of Results; Ritonavir; Spectrophotometry, Ultraviolet; Tazobactam | 2014 |
Antimicrobial activity of cefepime-tazobactam combination tested against clinical isolates of Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Humans; India; Penicillanic Acid; Tazobactam | 2014 |
Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.
Topics: Analytic Sample Preparation Methods; Anti-Bacterial Agents; Automation; Blood Chemical Analysis; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Ciprofloxacin; Humans; Isotopes; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Thienamycins; Time Factors | 2015 |
A green capillary zone electrophoresis method for the simultaneous determination of piperacillin, tazobactam and cefepime in pharmaceutical formulations and human plasma.
Topics: Cefepime; Cephalosporins; Dosage Forms; Electrophoresis, Capillary; Green Chemistry Technology; Humans; Linear Models; Penicillanic Acid; Piperacillin; Reproducibility of Results; Sensitivity and Specificity; Tazobactam | 2015 |
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Topics: Adult; Anti-Infective Agents; beta-Lactamases; Cefepime; Cephalosporins; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli; Hospitals; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; United States | 2015 |
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
Topics: Adaptation, Physiological; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Gene Expression; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protein Structure, Secondary; Protein Structure, Tertiary; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2015 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Should We Revisit the Nephrotoxic Potential of Piperacillin-Tazobactam as Well?
Topics: Acute Kidney Injury; Cefepime; Humans; Piperacillin; Tazobactam; Vancomycin | 2017 |
Reply to Manian.
Topics: Acute Kidney Injury; Cefepime; Humans; Piperacillin; Tazobactam; Vancomycin | 2017 |
Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Disk Diffusion Antimicrobial Tests; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Guidelines as Topic; Humans; Penicillanic Acid; Quality Control; Tazobactam | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Optimizing Empiric Antibiotic Selection in Sepsis: Turning Probabilities Into Practice.
Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Gram-Negative Bacteria; Humans; Meropenem; Probability; Sepsis; Tazobactam | 2018 |
Reply to MacFadden et al.
Topics: Bacteremia; Cefepime; Gram-Negative Bacteria; Humans; Meropenem; Piperacillin; Sepsis; Tazobactam | 2018 |
Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2018 |
Clinical efficacy and safety of cefepime-tazobactam in hospitalized patients in South India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Escherichia coli Infections; Female; Hospitalization; Humans; India; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Young Adult | 2018 |
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gene Expression; Hospitalization; Humans; Isoenzymes; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Plasmids; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tazobactam; United States | 2018 |
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation.
Topics: Anti-Bacterial Agents; Cefepime; Chromatography, Liquid; Drug Stability; Humans; Meropenem; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Temperature | 2018 |
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Chromatography, Liquid; Humans; Meropenem; Piperacillin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam | 2018 |
Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
Topics: Anti-Bacterial Agents; Cefepime; Critical Illness; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tazobactam | 2018 |
Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
Topics: Acute Kidney Injury; Aged; Cefepime; Critical Illness; Female; Humans; Incidence; Male; Meropenem; Middle Aged; Multivariate Analysis; Piperacillin; Retrospective Studies; Tazobactam; Vancomycin | 2019 |
Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia.
Topics: Adult; Anti-Bacterial Agents; Cefepime; Female; Humans; Immunity, Humoral; Male; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Aspiration; Tazobactam; Thrombocytopenia | 2019 |
Stability Studies of Antipyocyanic Beta-Lactam Antibiotics Used in Continuous Infusion.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Imipenem; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2019 |
In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cefepime; Drug Combinations; Enterobacteriaceae Infections; Humans; Imipenem; Microbial Sensitivity Tests; Tazobactam; Triazoles | 2020 |
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".
Topics: Anti-Bacterial Agents; Cefepime; Humans; Meropenem; Piperacillin; Protein Binding; Tazobactam | 2020 |
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".
Topics: Anti-Bacterial Agents; Cefepime; Humans; Meropenem; Piperacillin; Protein Binding; Tazobactam | 2020 |
In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Serine; Tazobactam; Thigh | 2021 |
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2021 |
Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum.
Topics: Cefepime; Chromatography, Liquid; Humans; Meropenem; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2021 |
Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Critical Illness; Humans; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Effects of piperacillin/tazobactam or cefepime on folinate dose in patients receiving high-dose methotrexate: A retrospective cohort study using Japanese administrative claims data.
Topics: Cefepime; Drug Therapy, Combination; Humans; Japan; Leucovorin; Methotrexate; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam | 2022 |
Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam | 2022 |
Emerging resistance to ceftriaxone treatment owing to different ampD mutations in Enterobacter roggenkampii.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefepime; Ceftriaxone; Drug Resistance, Bacterial; Enterobacter; Enterobacter cloacae; Humans; Liver Abscess; Microbial Sensitivity Tests; Mutation; Piperacillin; Tazobactam | 2022 |
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Cyclooctanes; Enterobacteriaceae; Gram-Negative Bacteria; Hydrazines; Lactams; Microbial Sensitivity Tests; Piperidines; Pseudomonas aeruginosa; Tazobactam | 2022 |
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Cyclooctanes; Humans; Imipenem; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
An Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Determination of 4 β-Lactam Antibiotics, Tazobactam, and Linezolid in Human Plasma Samples.
Topics: Anti-Bacterial Agents; Cefepime; Cefotaxime; Chromatography, High Pressure Liquid; Critical Illness; Drug Monitoring; Humans; Linezolid; Meropenem; Monobactams; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2022 |
Cefepime pharmacodynamic targets against Enterobacterales employing neutropenic murine lung infection and in vitro pharmacokinetic models.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Lung; Mice; Microbial Sensitivity Tests; Tazobactam | 2022 |
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.
Topics: Carbapenems; Cefepime; Ceftazidime; Phenotype; Pseudomonas aeruginosa; Tazobactam | 2022 |
Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates.
Topics: Amikacin; Amoxicillin; Anti-Bacterial Agents; Cefepime; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Genotype; Gentamicins; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin; Retrospective Studies; Tazobactam; Tobramycin; Whole Genome Sequencing | 2023 |
Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis-Reply.
Topics: Cefepime; Humans; Piperacillin; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2023 |
Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis.
Topics: Anti-Bacterial Agents; Cefepime; Drug Therapy, Combination; Humans; Piperacillin; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2023 |